Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 2/2007

01.02.2007 | Original Article

Endowing self-binding feature restores the activities of a loss-of-function chimerized anti-GM2 antibody

verfasst von: Yunfeng Zhao, Michael Russ, Marc Retter, Gary Fanger, Charles Morgan, Heinz Kohler, Sybille Muller

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

Our previous studies have described a rare type of antibody that spontaneously binds to itself, or homodimerizes. This self-binding, or autophilic antibody provides stronger protection against bacterial infection than a non-self-binding antibody with identical specificity and affinity, due to an increase of polymeric avidity. Furthermore, we have shown that a peptide derived from the self-binding domain of the autophilic T15 antibody can be crosslinked to the Fc carbohydrate of monoclonal antibodies specific for the B-cell receptor of B-cell tumors. These peptide-crosslinked antibodies can exert self-binding properties, leading to an increase in binding efficiency to the target cells as well as an increase in potential to induce apoptosis. Herein, we report a novel finding that crosslinking of the autophilic T15 peptide rescues a loss-of-function chimerized (ch) anti-GM2 antibody. The parental antibody demonstrates in vivo anti-tumor activity against melanoma xenografts. The T15 peptide-conjugated antibody shows the ability to bind to itself, as well as an increased binding to its antigen, ganglioside GM2. Moreover, the peptide-conjugated antibody also demonstrates an increased ability to bind to two GM2-positive tumor cell lines and notably important, restores its ability to induce apoptosis in two types of tumor cells. These results provide strong support for the clinical potential of the autophilic technology.
Literatur
1.
Zurück zum Zitat Walsh G (2004) Modern antibody-based therapeutics. BioPharm Int 1–5 Walsh G (2004) Modern antibody-based therapeutics. BioPharm Int 1–5
2.
Zurück zum Zitat Birkle S, Zeng G, Gao L, Yu RK, Aubry J (2003) Role of tumor-associated gangliosides in cancer progression (Review). Biochimie 85:455–463PubMedCrossRef Birkle S, Zeng G, Gao L, Yu RK, Aubry J (2003) Role of tumor-associated gangliosides in cancer progression (Review). Biochimie 85:455–463PubMedCrossRef
3.
Zurück zum Zitat Nakamura K, Tanaka Y, Shitara K, Hanai N (2001) Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions. Cancer Immunol Immunother 50:275–284PubMedCrossRef Nakamura K, Tanaka Y, Shitara K, Hanai N (2001) Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions. Cancer Immunol Immunother 50:275–284PubMedCrossRef
4.
Zurück zum Zitat Retter MW, Johnson JC, Peckham DW, Bannink JE, Bangur CS, Dresser K, Cai F, Foy TM, Fanger NA, Fanger GR, Woda B, Rock KL (2005) Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts. Cancer Res 65:6425–6434PubMedCrossRef Retter MW, Johnson JC, Peckham DW, Bannink JE, Bangur CS, Dresser K, Cai F, Foy TM, Fanger NA, Fanger GR, Woda B, Rock KL (2005) Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts. Cancer Res 65:6425–6434PubMedCrossRef
5.
Zurück zum Zitat Kang CY, Kohler H (1986) Immunoglobulin with complementary paratope and idiotope. J Exp Med 163:787–792PubMedCrossRef Kang CY, Kohler H (1986) Immunoglobulin with complementary paratope and idiotope. J Exp Med 163:787–792PubMedCrossRef
6.
Zurück zum Zitat Kang CY, Brunck TK, Kieber-Emmons T, Blalock JE, Kohler H (1988) Inhibition of self-binding antibodies (autobodies) by a VH-derived peptide. Science 240:1034–1036PubMedCrossRef Kang CY, Brunck TK, Kieber-Emmons T, Blalock JE, Kohler H (1988) Inhibition of self-binding antibodies (autobodies) by a VH-derived peptide. Science 240:1034–1036PubMedCrossRef
7.
Zurück zum Zitat Zhao Y, Lou D, Burke J, Kohler H (2002) Enhanced anti B-Cell tumor effects with anti-CD20 superantibody. J Immunother 25:57–62PubMedCrossRef Zhao Y, Lou D, Burke J, Kohler H (2002) Enhanced anti B-Cell tumor effects with anti-CD20 superantibody. J Immunother 25:57–62PubMedCrossRef
8.
Zurück zum Zitat Zhao Y, Kohler H (2002) Enhancing tumor targeting and apoptosis using non-covalent antibody homodimers. J Immunother 25:396–404PubMedCrossRef Zhao Y, Kohler H (2002) Enhancing tumor targeting and apoptosis using non-covalent antibody homodimers. J Immunother 25:396–404PubMedCrossRef
9.
Zurück zum Zitat Suzuki Y, Hirabayashi Y, Matsumoto N, Kato H, Hidari K, Tsuchiya K, Matsumoto M, Hoshino H, Tozawa H, Miwa M (1987) Aberrant expression of ganglioside and asialoglycosphingolipid antigens in adult T-cell leukemia cells. Jpn J Cancer Res 78:1112–1120PubMed Suzuki Y, Hirabayashi Y, Matsumoto N, Kato H, Hidari K, Tsuchiya K, Matsumoto M, Hoshino H, Tozawa H, Miwa M (1987) Aberrant expression of ganglioside and asialoglycosphingolipid antigens in adult T-cell leukemia cells. Jpn J Cancer Res 78:1112–1120PubMed
10.
Zurück zum Zitat Fernandes DM, Baird AM, Berg LJ, Rock KL (1999) A monoclonal antibody reactive with a 40-kDa molecule on fetal thymocytes and tumor cells blocks proliferation and stimulates aggregation and apoptosis. J Immunol 163:1306–1314PubMed Fernandes DM, Baird AM, Berg LJ, Rock KL (1999) A monoclonal antibody reactive with a 40-kDa molecule on fetal thymocytes and tumor cells blocks proliferation and stimulates aggregation and apoptosis. J Immunol 163:1306–1314PubMed
11.
Zurück zum Zitat Ward RE, McNamara-Ward M, Webb CF, Altman D, Lim PK, Tucker PW, Kohler H (1988) Regulation of an idiotype+ B cell lymphoma: effects of antigen and anti-idiotypic antibodies on proliferation and Ig secretion. J Immunol 141:340–345PubMed Ward RE, McNamara-Ward M, Webb CF, Altman D, Lim PK, Tucker PW, Kohler H (1988) Regulation of an idiotype+ B cell lymphoma: effects of antigen and anti-idiotypic antibodies on proliferation and Ig secretion. J Immunol 141:340–345PubMed
12.
Zurück zum Zitat Hasbold J, Klaus GGB (1990) Anti-immunoglobulin antibodies induce apoptosis in immature B cell lymphomas. Eur J Immunol 20:1685–1690PubMed Hasbold J, Klaus GGB (1990) Anti-immunoglobulin antibodies induce apoptosis in immature B cell lymphomas. Eur J Immunol 20:1685–1690PubMed
13.
Zurück zum Zitat Wallen-Ohman M, Lonnbro P, Schon A, Borrebaeck CAK (1993) Antibody-induced apoptosis in a human leukemia cell line is energy dependent: thermochemical analysis of cellular metabolism. Cancer Lett 75:103–109PubMedCrossRef Wallen-Ohman M, Lonnbro P, Schon A, Borrebaeck CAK (1993) Antibody-induced apoptosis in a human leukemia cell line is energy dependent: thermochemical analysis of cellular metabolism. Cancer Lett 75:103–109PubMedCrossRef
14.
Zurück zum Zitat Ghetie MA, Picker LJ, Richardson JA, Tucker K, Uhr JW, Vitetta ES (1994) Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest. Blood 83:1329–1336PubMed Ghetie MA, Picker LJ, Richardson JA, Tucker K, Uhr JW, Vitetta ES (1994) Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest. Blood 83:1329–1336PubMed
15.
Zurück zum Zitat Ghetie MA, Podar EM, Ilgen A, Gordon BE, Uhr JW, Vitetta ES (1997) Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proc Natl Acad Sci USA 94:7509–7514PubMedCrossRef Ghetie MA, Podar EM, Ilgen A, Gordon BE, Uhr JW, Vitetta ES (1997) Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proc Natl Acad Sci USA 94:7509–7514PubMedCrossRef
16.
Zurück zum Zitat Chester K, Pedley B, Tolner B, Violet J, Mayer A, Sharma S, Boxer G, Green A, Nagl S, Begent R (2004) Engineering antibodies for clinical applications in cancer (Review). Tumour Biol 25:91–98PubMedCrossRef Chester K, Pedley B, Tolner B, Violet J, Mayer A, Sharma S, Boxer G, Green A, Nagl S, Begent R (2004) Engineering antibodies for clinical applications in cancer (Review). Tumour Biol 25:91–98PubMedCrossRef
17.
Zurück zum Zitat Gorman SD, Clark MR (1990) Humanisation of monoclonal antibodies for therapy (Review). Semin Immunol 2:457–466PubMed Gorman SD, Clark MR (1990) Humanisation of monoclonal antibodies for therapy (Review). Semin Immunol 2:457–466PubMed
18.
19.
Zurück zum Zitat Ehrlich PH, Moyle WR, Moustafa ZA, Canfield RE (1982) Mixing two monoclonal antibodies yields enhanced affinity for antigen. J Immunol 128:2709–2713PubMed Ehrlich PH, Moyle WR, Moustafa ZA, Canfield RE (1982) Mixing two monoclonal antibodies yields enhanced affinity for antigen. J Immunol 128:2709–2713PubMed
20.
Zurück zum Zitat Greenspan NS, Monafo WJ, Davie JM (1987) Interaction of IgG3 anti-streptococcal group A carbohydrate (GAC) antibody with streptococcal group A vaccine: enhancing and inhibiting effects of anti-GAC, anti-isotypic, and anti-idiotypic antibodies. J Immunol 138:285–292PubMed Greenspan NS, Monafo WJ, Davie JM (1987) Interaction of IgG3 anti-streptococcal group A carbohydrate (GAC) antibody with streptococcal group A vaccine: enhancing and inhibiting effects of anti-GAC, anti-isotypic, and anti-idiotypic antibodies. J Immunol 138:285–292PubMed
21.
Zurück zum Zitat Greenspan NS, Dacek DA, Cooper LJ (1988) Fc region-dependence of IgG3 anti-streptococcal group A carbohydrate antibody functional affinity. I. The effect of temperature. J Immunol 141:4276–4282PubMed Greenspan NS, Dacek DA, Cooper LJ (1988) Fc region-dependence of IgG3 anti-streptococcal group A carbohydrate antibody functional affinity. I. The effect of temperature. J Immunol 141:4276–4282PubMed
22.
Zurück zum Zitat Chapman PB, Yuasa H, Houghton AN (1990) Homophilic binding of mouse monoclonal antibodies against GD3 ganglioside. J Immunol 145:891–898PubMed Chapman PB, Yuasa H, Houghton AN (1990) Homophilic binding of mouse monoclonal antibodies against GD3 ganglioside. J Immunol 145:891–898PubMed
23.
Zurück zum Zitat Yan X, Evans SV, Kaminki MJ, Gillies SD, Reisfeld RA, Houghton AN, Chapman PB (1996) Characterization of an Ig VH idiotope that results in specific homophilic binding and increased avidity for antigen. J Immunol 157:1582–1588PubMed Yan X, Evans SV, Kaminki MJ, Gillies SD, Reisfeld RA, Houghton AN, Chapman PB (1996) Characterization of an Ig VH idiotope that results in specific homophilic binding and increased avidity for antigen. J Immunol 157:1582–1588PubMed
24.
Zurück zum Zitat Kaveri SV, Halpern R, Kang CY, Kohler H (1990) Self-binding antibodies (autobodies) form specific complexes in solution. J Immunol 145:2533–2538PubMed Kaveri SV, Halpern R, Kang CY, Kohler H (1990) Self-binding antibodies (autobodies) form specific complexes in solution. J Immunol 145:2533–2538PubMed
25.
Zurück zum Zitat Halpern R, Kaveri SV, Kohler H (1991) Human anti-phosphorylcholine antibodies share idiotopes and are self-binding. J Clin Invest 88:476–482PubMedCrossRef Halpern R, Kaveri SV, Kohler H (1991) Human anti-phosphorylcholine antibodies share idiotopes and are self-binding. J Clin Invest 88:476–482PubMedCrossRef
26.
Zurück zum Zitat Zhao Y, Russ M, Morgan C, Muller S, Kohler H (2005) Therapeutic applications of superantibodies. Drug Discov Today 10:1231–1236PubMedCrossRef Zhao Y, Russ M, Morgan C, Muller S, Kohler H (2005) Therapeutic applications of superantibodies. Drug Discov Today 10:1231–1236PubMedCrossRef
Metadaten
Titel
Endowing self-binding feature restores the activities of a loss-of-function chimerized anti-GM2 antibody
verfasst von
Yunfeng Zhao
Michael Russ
Marc Retter
Gary Fanger
Charles Morgan
Heinz Kohler
Sybille Muller
Publikationsdatum
01.02.2007
Verlag
Springer-Verlag
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 2/2007
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-006-0182-2

Weitere Artikel der Ausgabe 2/2007

Cancer Immunology, Immunotherapy 2/2007 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.